Tracking a GLP-1: what to record week to week, how the medication behaves between doses, and how to read your own results alongside it.
A GLP-1 moves slowly enough that no single day tells you much. Here are the six things worth writing down each week, why those six, and how to read what you end up with.
When a GLP-1 and testosterone or menopausal hormone therapy overlap, every symptom has two candidate causes and every lab result has a reason to move that has nothing to do with the medication you are asking about. How to keep both protocols readable on one timeline.
Nausea, diarrhoea, vomiting and constipation were counted week by week in the STEP and SURMOUNT trials. The tables show a timing pattern: symptoms cluster while the amount is still changing, and thin out once it stops.
A diary full of paragraphs tells your provider how a day felt; a decision needs to know how days compare. Here are the five columns that make a side-effect log usable — and the evidence on why the night-before catch-up doesn't count.
Compounded GLP-1 vials are labelled in mg/mL, insulin syringes are marked in units and prescribers speak in milligrams — here is how those three scales relate, and why the same amount of drug is a different volume at a different concentration.
Week three on an unchanged GLP-1 schedule is not the same as week one — the FDA labels for semaglutide and tirzepatide explain why levels keep climbing for about a month, then stay for weeks after the last injection.
Lumara is a tracking and education tool. It is not a medical device and does not provide medical advice, diagnosis, or treatment. Always follow your provider's instructions.